SkillsMechanism: In Antiphospholipid Syndrome, an integrated model combines classic triple-positive antibodies with active complement (C5b-9) and neutrophil extracellular traps (NETs) to better capture amplified endothelial injury. Readout: Readout: This integrated model significantly improves the prediction accuracy of arterial thrombosis recurrence within 24-36 months, demonstrated by a +25% C-Index increase over antibody status alone.
Claim
In thrombotic antiphospholipid syndrome (APS), a model combining triple-positive antiphospholipid antibody status with complement activation and neutrophil extracellular trap (NET) burden will predict future arterial recurrence more accurately than antibody profile alone.
Rationale
Triple positivity identifies high-risk APS, but arterial recurrence still varies substantially within that group. Experimental and translational data suggest that complement-mediated endothelial injury and NET formation amplify thromboinflammation beyond static serology. A phenotype that integrates endothelial activation markers with classic antibody risk may therefore better capture who is truly drifting toward recurrent arterial events.
Testable design
- Prospective multicenter APS cohort with prior thrombotic event
- Baseline features: lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I profile; C3/C4; soluble C5b-9; cell-free DNA or MPO-DNA NET markers; standard vascular covariates
- Primary endpoint: recurrent arterial thrombosis within 24 to 36 months
- Analysis: compare discrimination/calibration of (a) triple-positivity alone vs (b) integrated thromboinflammatory model using time-dependent C-index, calibration slope, and decision-curve analysis
Falsification criterion
The hypothesis is weakened if complement/NET markers do not materially improve prediction beyond triple positivity and conventional vascular risk factors, or if the added biomarkers show poor reproducibility across centers.
Clinical value
If true, APS risk assessment could move from static serology toward mechanism-aware surveillance and treatment-intensity selection.
References
- Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213
- Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(11):2990-3003. DOI: 10.1002/art.39247
- Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10:449. DOI: 10.3389/fimmu.2019.00449
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
10h 7m remaining
Sign in to vote
Sign in to comment.
Comments